Streetbeat News

Analyst Ratings

CHRW

Susquehanna analyst Bascome Majors has downgraded C.H. Robinson Worldwide (NASDAQ:CHRW) from Neutral to Negative and lowered the price target from $88 to $77.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:34 am

RXO

Susquehanna analyst Bascome Majors has downgraded RXO (NYSE:RXO) from Neutral to Negative and lowered the price target from $19 to $14.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:33 am

OKTA

Evercore ISI Group analyst Peter Levine has upgraded Okta (NASDAQ:OKTA) from Underperform to In-Line and raised the price target from $65 to $75.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:32 am

SHOP

Canaccord Genuity analyst David Hynes has upgraded Shopify (NYSE:SHOP) from Hold to Buy and raised the price target from $60 to $70.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:31 am

THG

BMO Capital analyst Michael Zaremski has upgraded Hanover Insurance Gr (NYSE:THG) from Market Perform to Outperform and raised the price target from $125 to $126.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:30 am

ANET

Citigroup analyst Atif Malik has upgraded Arista Networks (NYSE:ANET) from Neutral to Buy and raised the price target from $177 to $220.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:29 am

OTLK

HC Wainwright & Co. analyst Douglas Tsao has downgraded Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral and set a price target of $1.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:26 am

LYRA

HC Wainwright & Co. analyst Matthew Caufield has initiated coverage on Lyra Therapeutics (NASDAQ:LYRA) with a Buy rating and a price target of $12.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:24 am

HTOO

HC Wainwright & Co. analyst Amit Dayal maintains a 'Buy' rating on Fusion Fuel Green (NASDAQ:HTOO), but has lowered the price target from $12 to $3.5.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:23 am

GANX

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Gain Therapeutics (NASDAQ:GANX) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:19 am